Search Results 1411-1420 of 19150 for Neutrophil

1. A Study to Evaluate Daratumumab and Ibrutinib to Treat Relapsed / Refractory Chronic Lymphocytic Leukemia Treatment (DIRECT) - Mayo Clinic

   Absolute neutrophil count ≥ 1000/mm^3;; Platelets ≥ 50,000/mm^3;; Serum creatinine ≤ 1.5 x ULN (minimal acceptable creatinine clearance (CLcr) > 25 ml/min ...

2. Study To Determine The Effectiveness And Safety Of Dupilumab In Adult And Adolescent Patients With Eosinophilic Esophagitis (EoE) - Mayo Clinic

   Neutrophils <1.5 × 103/μL;; Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2. NOTE: If an abnormal value is detected at screening, a ...

3. A Study Of 177Lu-FAP-2286 In Advanced Solid Tumors - Mayo Clinic

   Absolute neutrophil count (ANC) ≥ 1.5 × 109/L; ii. Platelets \> 100 × 109/L; and iii.Hemoglobin ≥ 9 g/dL. b. Hepatic Function: i. Aspartate ...

4. NRG-GY012 “A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, And The Combinations Of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5356 (Capivasertib) In Women With Recurrent, Persistent Or Metastatic Endometrial Cancer. A Multi-Arm Trial For Women With Recurrent Or Persistent Endometrial Cancer” - Mayo Clinic

   Platelet count >= 100 x 10^9/L - Absolute neutrophil count (ANC) >= 1.5 x 10^9/L - Hemoglobin > 9 mg/dL. Serum creatinine =< the institutional upper limit ...

5. Efineptakin alfa (NT-I7) Plus Pembrolizumab for the Treatment of Recurrent Glioblastoma - Mayo Clinic

   * Absolute neutrophil count (ANC) \>= 1500/mm\^3 (obtained =\< 15 days prior to registration) * Platelet count \>= 100,000/mm\^3 (obtained =\< 15 days prior ...

6. A Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy - Mayo Clinic

   Absolute neutrophil count ≥ 1,500/μL;; Platelets ≥ 100,000/μL;; Hemoglobin ≥ 0 g/dL;; Serum creatinine ≤ 1.5 xp peur limit of normal (ULN) or calculated ...

7. A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers - Mayo Clinic

   - Absolute neutrophil count >= 1,500/mcL - Hemoglobin >= 9.0 g/dl - Platelets >= 100,000/mcL - Total bilirubin =< 1.5 x institutional upper limit of normal ...

8. Doxorubicin Hydrochloride, Cyclophosphamide, And Paclitaxel With Or Without Bevacizumab In Treating Patients With Lymph Node-Positive Or High-Risk, Lymph Node-Negative Breast Cancer - Mayo Clinic

   Within =< 8 weeks prior to randomization: Absolute neutrophil count >= 1,000/mm^3. Within =< 8 weeks prior to randomization: Platelet count >= 100,000/mm^3.

9. A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302) - Mayo Clinic

   Absolute neutrophil count (ANC) < 2 × 10^9/L (2000 cells/mm^3). Serum creatinine level > 1.5 × ULN or estimated glomerular filtration rate (GFR) < 30 mL/min ...

10. Testing The Use Of The Combination Of Selumetinib And Olaparib Or Selumetinib Alone Targeted Treatment For RAS Pathway Mutant Recurrent Or Persistent Ovarian And Endometrial Cancers, A ComboMATCH Treatment Trial - Mayo Clinic

    - Absolute neutrophil count (ANC) >= 1,500/mcl (within 14 days prior to registration) - Patients must have creatinine clearance estimated of >= 50 mL/min ...